Topics

ThromboGenics NV and BioInvent International Company Profile

01:11 EDT 24th July 2019 | BioPortfolio

ThromboGenics is a biotechnology company focused on the discovery and development of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anticoagulant, and TB-403 (anti-PlGF) for cancer.


News Articles [451 Associated News Articles listed on BioPortfolio]

Notice to Annual General Meeting in BioInvent International AB

LUND, Sweden, March 19, 2019 /PRNewswire/ -- The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting (the "AGM") to be h...

Notice of Extraordinary General Meeting in BioInvent International AB

LUND, Sweden, Feb. 25, 2019 /PRNewswire/ -- The shareholders of BioInvent International AB (publ) (BINV) Reg. No. 556537-7263, are hereby invited to attend the Extraordinary General Meeting (the "...

BioInvent Announces Publication of Review Article in Frontiers in Immunology on Resistance to Antibody Drugs

- Data demonstrate that the activating and inhibitory Fc gamma receptors control antitumor immunity LUND, Sweden, March 12, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV), a company ...

BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma

BioInvent is currently investigating this combination in Phase I/IIa study Significant unmet medical need in mantle cell lymphoma LUND, Sweden, Jan. 30, 2019 /PRNewswire/ -- BioInvent Internationa...

BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application

LUND, Sweden, July 4, 2019 /PRNewswire/ -- BioInvent International AB (BINV) today announced it will receive a $0.5 million milestone payment related to the acceptance by the U.S. Food and Drug Ad...

Särläkemedelsstatus till Bioinvent

Lundabaserade Bioinvent har fått särläkemedelsstatus från FDA för sin kandidat mot mantelcellslymf

BioInvent’s Deal with Roche – Are Early-Stage Deals on the Rise?

In this interview Fintan Walton speaks with Martin Wiles, Vice President of Business Development of BioInvent International based in Lund Sweden about the deal which Bio Invent has entered into with R...

Transgene and BioInvent extend OV development for solid tumor collaboration

Transgene and BioInvent will extend its collaboration to co-develop multi-functional oncolytic viruses for the treatment of solid tumors.

PubMed Articles [521 Associated PubMed Articles listed on BioPortfolio]

The International Childbirth Initiative: 12 steps to safe and respectful MotherBaby-Family maternity care.

Health promotion by International Olympic Sport Federations: priorities and barriers.

To identify changes in International Federations' priorities and the barriers to implementing athlete and global health initiatives. Results should influence the work of the International Federation m...

History of the International Association of Paediatric Dentistry: A 50-year perspective.

This paper demonstrates how the International Association of Paediatric Dentistry (IAPD) arose from small beginnings in 1967. What started as an International Forum on Child Dental Health in London gr...

International Nursing Review: Celebrating Induction into the 2018 International Academy of Nursing Editors' Hall of Fame.

Graduate mobility: Where do dentistry Graduates Choose to Practice?

The international higher education market has grown and developed rapidly. International students generate attractive income for their host university, and gaining an international education benefits...

Clinical Trials [1212 Associated Clinical Trials listed on BioPortfolio]

Epidogs International Inventory of Seizure Alert Dogs

This international research project looks at the reliability of canine seizure alerting behaviour in epilepsy patients. In the first stage an international database to identify the size an...

International AGD Database; Determinants of AGD and Establishment of Normative Data

Aim: To collate data on Anogenital Distance (AGD) from several population studies to build an international database for Anogenital Distance (AGD) Primary objective: To build a database p...

International Study on NoSocomial Pneumonia in Intensive CaRE

The International study on NoSocomial Pneumonia in Intensive CaRE (PneumoINSPIRE) is a prospective, international, multicentre, observational, cohort study. The study aims to provide up-to...

Effectiveness Study of the International Child Development Program

The objective of this study is to evaluate the effect of the International Child Development Program (ICDP). Research questions to be answered: 1. Does the ICDP affect children's psycho...

H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis

LCH III is an international, multicentric, prospective clinical study comprised of: - a randomized clinical trial for multisystem "RISK" patients and - a randomized clinical trial ...

Companies [1320 Associated Companies listed on BioPortfolio]

ThromboGenics NV and BioInvent International

ThromboGenics is a biotechnology company focused on the discovery and development of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead...

BioInvent International AB and ThromboGenics NV

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based

BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company's pipeline...

Bioinvent International AB

BioInvent International is a unique company dedicated to working with clients to ensure their success in the discovery, development and manufacture of antibody drugs. The discovery of new drug targets...

BioInvent International AB (publ)

BioInvent is dedicated to helping realize the innovator's innovation originating from any drug discovery labs in corporate or academic environments. Based on this commitment, we actively seek collabor...

More Information about "ThromboGenics NV and BioInvent International" on BioPortfolio

We have published hundreds of ThromboGenics NV and BioInvent International news stories on BioPortfolio along with dozens of ThromboGenics NV and BioInvent International Clinical Trials and PubMed Articles about ThromboGenics NV and BioInvent International for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ThromboGenics NV and BioInvent International Companies in our database. You can also find out about relevant ThromboGenics NV and BioInvent International Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Corporate Database Quicklinks



Searches Linking to this Company Record